NR1H4 and hepatocellular carcinoma: The combination of UDCA, an FXR antagonist with the targeted therapeutic drug sorafenib, shows an efficacious response in HCC by inhibiting cell proliferation and inducing apoptosis through the reactive-oxygen-species-dependent activation of ERK and the dephosphorylation of STAT3 [211].